The company refreshed its board and appointed a CEO with commercialisation experience to drive the roadmap and growth.

Under new CEO David Morris, the plan is to convert the proteomics platform into a scalable diagnostics business and pursue a capital-light distribution model via partners rather than in-house sales teams.

Proteomics International Laboratories has been granted a US patent for PromarkerEndo, expanding its US intellectual property stack for the endometriosis diagnostic blood test.

PromarkerEndo aims to detect endometriosis non-invasively and guide treatment, addressing a global unmet need as endometriosis affects roughly one in nine women and is often diagnosed after a seven-year delay requiring invasive procedures.

The patent supports potential partnerships and licensing, with ongoing work to advance regulatory reimbursement and broaden market reach.

David Morris says the US patent grant is a critical commercialization milestone, validating PromarkerEndo’s novelty and potential.

Morris describes the USPTO grant as validation of the test’s novelty and commercial potential and a milestone for the company’s commercialization strategy.

The company relocated its registered office to the Harry Perkins Institute to support precision diagnostics and bio-analytical operations, aligning with 2026 strategic moves such as pursuing stock exchange quotations for new shares and informing option holders about expiration dates.

Reimbursement strategies include Australian Medicare Benefits Schedule listing and US payer-by-payer reimbursement, aiming to unlock broader patient access and revenue.

The patent is viewed as evidence of novelty and commercial potential and a milestone in shifting from R&D to commercial traction.

Proteomics plans to appoint an Australian distributor and launch local controlled market releases for PromarkerEndo in H1 FY2027, with a US distribution network and reimbursement submissions planned for H2 FY2027.

Share reaction was positive, with Proteomics shares rising about 23% on the patent news.